Error with arthritis medication as ‘stop using immediately’ message issued

A group of arthritis is remembered due to a labeling error. Drugs and Health Products Editing Agency (MHRA) said on Wednesday that some packages were distributed to pharmacies with wrong labels.

Mhra reported that the label in a imported warehouse-Medrone group of manufacturer Maxearn Limited was “released with a mistake”. They stated that the vial label contains false information about volume and total vial content.

MHRA explained: “Label, correct total bottle content 2 ml 80 mg (40mg/ml methylprednisolone acetate concentration) when the total vial content is 40 ml in 1 ml.

“Maxearn contacted its distributors, 32 packs were distributed to pharmacies. The remaining units provided to the distributor were quarantined.

“The error only affects the parallel imported product re -packaged by Maxearn, packages from other sources are not affected and should continue to be distributed.”

DEP-Medron is injected directly into the joints and soft tissues for the treatment of rheumatoid arthritis, osteoarthritis, bursitis and similar inflammatory conditions.

Mhra made sure that patients did not require alarm after instructing to stop the distribution of the party affected by health care providers.

“Maxearn may confirm that 32 packages have been released by the distributor.

“This party should apply to the patient to be aware of this error and provide relevant clinical advice to patients.”

For those concerned, MHRA explained: “This is a pharmacy and wholesaler level recall by patients. There is no need for any other procedure by patients. Warehouse-Medron is applied under the supervision of a healthcare professional. Patients receiving this party will be contacted by your healthcare professional.

“Patients who have negative reactions or have any questions about the drug should receive medical aid. Mhra yellow card scheme and suspicious negative reactions should also be reported.”